Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
An open randomised study of the efficacy of standard radiotherapy with and without the addition of SRL172 (Mycobacterium vaccae) in the treatment of patients with small cell lung cancer (SIRON 13)
Source of recordUK Trials
ISRCTNISRCTN22342362
Date ISRCTN assigned19/08/2002
Local reference number(s)SIRON 13
Public titleAn open randomised study of the efficacy of standard radiotherapy with and without the addition of SRL172 (Mycobacterium vaccae) in the treatment of patients with small cell lung cancer (SIRON 13)
Scientific title
AcronymN/A
Disease/condition/study domainLung (small cell)
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Patients should be aged at least 18 years with histologically and/or cytologically confirmed unresectable small cell lung cancer, which includes limited or extensive stage disease
2. There should be presence of measurable or evaluable disease
3. Patients should be World Health Organisation (WHO) performance status 0-2
4. Serum creatinine <140 micromol/l or creatinine clearance >50 ml/min (if serum creatinine 120-140 micromol/l) if receiving cisplatin. If receiving carboplatin, creatinine clearance >20ml/min
5. Life expectance >3 months
6. Written informed consent
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated start date01/01/2000
Status of trialCompleted
Target number of participantsNot provided at time of registration
Interventions1. Standard chemotherapy (as per protocol)
2. Standard chemotherapy + SRL172 injections (as per protocol)
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingNot available
Sponsor nameUK Co-ordinating Committee for Cancer Research (UKCCCR)
Sponsor detailsMRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Sponsor telephone+44 (0) 20 7670 4723
Sponsor fax+44 (0) 20 7670 4818
Sponsor emailregister@ctu.mrc.ac.uk
Sponsor websitehttp://www.ctu.mrc.ac.uk/ukcccr/home.html
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN22342362
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central